NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026)

NewAmsterdam Pharma has disclosed Research & Development across 4 years of filings, most recently posting $38.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $38.0 million, down 15.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $135.1 million (down 12.12% YoY), and the FY2025 annual result was $141.8 million, down 6.32% from the prior year.
• Research & Development came in at $38.0 million for Q1 2026 at NewAmsterdam Pharma, down from $38.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $44.8 million in Q1 2025 to a low of $27.5 million in Q2 2025.
• The 4-year median for Research & Development is $38.4 million (2024), against an average of $37.7 million.
• Across the five-year window, Research & Development rose 11.76% in 2024 and declined 28.3% in 2025, its largest moves.
• NewAmsterdam Pharma's Research & Development stood at $41.3 million in 2023, then retreated by 15.49% to $34.9 million in 2024, then increased by 10.6% to $38.6 million in 2025, then fell by 1.52% to $38.0 million in 2026.
• The last three Research & Development figures came in at $38.0 million (Q1 2026), $38.6 million (Q4 2025), and $31.0 million (Q3 2025), per Business Quant data.